MCID: SVR004
MIFTS: 71

Severe Combined Immunodeficiency

Categories: Rare diseases, Immune diseases

Aliases & Classifications for Severe Combined Immunodeficiency

Summaries for Severe Combined Immunodeficiency

NIH Rare Diseases : 49 Severe combined immunodeficiencies (SCID) are inheritedimmune system disorders characterized by abnormalities with responses of both T cells and B cells (specific types of white blood cells needed for immune system function). Common signs and symptoms include an increased susceptibility to infections including ear infections; pneumonia or bronchitis; oral thrush; and diarrhea. Due to recurrent infections, children with SCID do not grow and gain weight as expected (failure to thrive). SCID may be caused by mutations in any of several genes and can be inherited in an X-linked recessive (most commonly) or autosomal recessive manner. The most common type of SCID is called X-linked severe combined immunodeficiency (XSCID). Another form of SCID is caused by a deficiency of the enzyme adenosine deaminase (ADA). Infections are treated with specific antibiotic, antifungal, and antiviral agents and administration of intravenous (IV) immunoglobulin. The most effective treatment is transplantation of blood-forming stem cells from the bone marrow of a healthy person. Last updated: 6/28/2017

MalaCards based summary : Severe Combined Immunodeficiency, also known as scid, is related to severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-negative and severe combined immunodeficiency with sensitivity to ionizing radiation, and has symptoms including recurrent urinary tract infections, abnormality of the dentition and microcephaly. An important gene associated with Severe Combined Immunodeficiency is IL7R (Interleukin 7 Receptor), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Adenosine and alemtuzumab have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are Increased viability with tamoxifen and hematopoietic system

Disease Ontology : 12 A combined T cell and B cell immunodeficiency that is caused by a defect in several genes encoding for B and T lymphocytes resulting in individuals with non-functional immune systems.

Wikipedia : 72 Severe combined immunodeficiency, SCID, also known as alymphocytosis, Glanzmann–Riniker syndrome, severe... more...

Related Diseases for Severe Combined Immunodeficiency

Diseases related to Severe Combined Immunodeficiency via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 236)
# Related Disease Score Top Affiliating Genes
1 severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-negative 34.6 JAK3 RAG1 RAG2
2 severe combined immunodeficiency with sensitivity to ionizing radiation 34.6 DCLRE1C LIG4
3 severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-positive 34.5 CD3D IL7R PTPRC
4 jak3-deficient severe combined immunodeficiency 33.9 IL2 IL9 JAK3
5 t-b+ severe combined immunodeficiency due to cd3delta/cd3epsilon/cd3zeta 33.7 CD3D CD3E
6 severe combined immunodeficiency, x-linked 33.5 ADA IL2 IL2RG IL7 IL7R IL9
7 immunodeficiency 19 33.3 CD3D JAK3 ZAP70
8 immunodeficiency 18 32.7 CD3D CD3E PTPRC
9 omenn syndrome 32.6 ADA DCLRE1C IL2RG IL7R LIG4 RAG1
10 bare lymphocyte syndrome, type ii 32.5 IL7R RFX5 RFXAP
11 recombinase activating gene 1 deficiency 31.8 RAG1 RAG2
12 artemis deficiency 31.8 DCLRE1C LIG4 PRKDC RAG1
13 interleukin-7 receptor alpha deficiency 31.5 IL2RG IL7 IL7R JAK3
14 combined cellular and humoral immune defects with granulomas 30.8 RAG1 RAG2
15 bare lymphocyte syndrome, type i 30.5 RFX5 RFXAP ZAP70
16 lig4 syndrome 29.9 DCLRE1C LIG4 NHEJ1 PRKDC RAG1 RAG2
17 lymphopenia 29.8 IL2 IL2RG IL7 IL7R RAG1
18 t cell deficiency 29.8 IL2 IL7R PTPRC ZAP70
19 anaplastic large cell lymphoma 29.4 IL9 JAK3 PTPRC
20 leukemia, chronic lymphocytic 28.6 IL2 IL7 PTPRC ZAP70
21 combined immunodeficiency, x-linked 26.3 ADA AK2 CD3D DCLRE1C IL2 IL2RG
22 severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-negative, nk cell-negative, due to adenosine deaminase deficiency 12.6
23 severe combined immunodeficiency with microcephaly, growth retardation, and sensitivity to ionizing radiation 12.5
24 zap70-related severe combined immunodeficiency 12.4
25 achondroplasia and severe combined immunodeficiency 12.4
26 severe combined immunodeficiency, atypical 12.3
27 short-limb skeletal dysplasia with severe combined immunodeficiency 12.2
28 reticular dysgenesis 12.2
29 adenosine deaminase deficiency 12.2
30 immunodeficiency 26 with or without neurologic abnormalities 11.8
31 immunodeficiency 49 11.7
32 immunodeficiency 8 11.6
33 immunodeficiency 22 11.6
34 immunodeficiency 11 11.4
35 immunodeficiency 15 11.4
36 immunodeficiency 24 11.4
37 immunodeficiency 17 11.4
38 zap-70 deficiency 11.4
39 t-cell immunodeficiency, congenital alopecia, and nail dystrophy 11.3
40 immunodeficiency 9 11.1
41 immunodeficiency 52 11.0
42 gastrointestinal defects and immunodeficiency syndrome 10.8
43 purine nucleoside phosphorylase deficiency 10.8
44 immunoskeletal dysplasia with neurodevelopmental abnormalities 10.8
45 cd3zeta deficiency 10.8
46 recombinase activating gene 2 deficiency 10.8
47 cd45 deficiency 10.8
48 coronin-1a deficiency 10.8
49 dock2 deficiency 10.8
50 malignant histiocytosis 10.3 DCLRE1C RAG1 RAG2

Graphical network of the top 20 diseases related to Severe Combined Immunodeficiency:



Diseases related to Severe Combined Immunodeficiency

Symptoms & Phenotypes for Severe Combined Immunodeficiency

Human phenotypes related to Severe Combined Immunodeficiency:

31 (show all 16)
# Description HPO Frequency HPO Source Accession
1 recurrent urinary tract infections 31 occasional (7.5%) HP:0000010
2 abnormality of the dentition 31 occasional (7.5%) HP:0000164
3 microcephaly 31 occasional (7.5%) HP:0000252
4 chronic otitis media 31 occasional (7.5%) HP:0000389
5 sensorineural hearing impairment 31 occasional (7.5%) HP:0000407
6 skin rash 31 frequent (33%) HP:0000988
7 failure to thrive 31 hallmark (90%) HP:0001508
8 alopecia 31 frequent (33%) HP:0001596
9 splenomegaly 31 occasional (7.5%) HP:0001744
10 lymphopenia 31 frequent (33%) HP:0001888
11 fever 31 hallmark (90%) HP:0001945
12 chronic diarrhea 31 hallmark (90%) HP:0002028
13 recurrent respiratory infections 31 hallmark (90%) HP:0002205
14 hepatomegaly 31 occasional (7.5%) HP:0002240
15 severe combined immunodeficiency 31 hallmark (90%) HP:0004430
16 sepsis 31 hallmark (90%) HP:0100806

GenomeRNAi Phenotypes related to Severe Combined Immunodeficiency according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with tamoxifen GR00120-A 8.62 CD3E PRKDC

MGI Mouse Phenotypes related to Severe Combined Immunodeficiency:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.3 LIG4 IL2RG ADA IL7 CD3D IL7R
2 endocrine/exocrine gland MP:0005379 10.28 LIG4 IL2RG ADA IL7 IL7R CD3E
3 cellular MP:0005384 10.27 JAK3 IL2 IL2RG ADA IL7R CD3E
4 immune system MP:0005387 10.25 LIG4 IL2RG ADA IL7 CD3D IL7R
5 digestive/alimentary MP:0005381 10.13 IL2 IL2RG ADA IL9 JAK3 RAG2
6 neoplasm MP:0002006 9.85 IL2RG IL7R CD3E IL2 NHEJ1 RAG2
7 liver/biliary system MP:0005370 9.8 IL2 ADA LIG4 RAG1 RAG2 PRKDC
8 normal MP:0002873 9.56 IL2RG ADA IL7R IL9 RAG1 RAG2
9 respiratory system MP:0005388 9.23 IL2 IL2RG ADA RAG1 RAG2 PRKDC

Drugs & Therapeutics for Severe Combined Immunodeficiency

Drugs for Severe Combined Immunodeficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 87)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-61-7 60961
2
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1 216503-57-0
3
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1 55-98-1 2478
4
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
5
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
6
Vidarabine Approved, Investigational Phase 2, Phase 3,Phase 1 24356-66-9 21704 32326
7 Alkylating Agents Phase 2, Phase 3,Phase 1
8 Anti-Infective Agents Phase 2, Phase 3,Phase 1
9 Antimetabolites Phase 2, Phase 3,Phase 1
10 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
11 Antirheumatic Agents Phase 2, Phase 3,Phase 1
12 Antiviral Agents Phase 2, Phase 3,Phase 1
13 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
14 Antibodies Phase 3,Phase 1,Phase 2
15 gamma-Globulins Phase 3
16 Immunoglobulins Phase 3,Phase 1,Phase 2
17 Immunoglobulins, Intravenous Phase 3
18 Rho(D) Immune Globulin Phase 3
19
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
20
Melphalan Approved Phase 2 148-82-3 460612 4053
21 Thiotepa Approved, Investigational Phase 2 52-24-4 5453
22
Hydroxyurea Approved Phase 2 127-07-1 3657
23
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
24
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
25
Mycophenolate mofetil Approved, Investigational Phase 2,Phase 1 128794-94-5 5281078
26
Mycophenolic acid Approved Phase 2,Phase 1 24280-93-1 446541
27
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
28
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
29
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
30
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
31 Analgesics Phase 2,Phase 1
32 Anti-Arrhythmia Agents Phase 2,Phase 1
33 Neurotransmitter Agents Phase 2,Phase 1
34 Peripheral Nervous System Agents Phase 2,Phase 1
35 Vasodilator Agents Phase 2,Phase 1
36 Antilymphocyte Serum Phase 1, Phase 2
37 Nucleic Acid Synthesis Inhibitors Phase 2
38 Anesthetics Phase 1, Phase 2
39 Anti-Bacterial Agents Phase 2,Phase 1
40 Antibiotics, Antitubercular Phase 2,Phase 1
41 Antitubercular Agents Phase 2,Phase 1
42 Calcineurin Inhibitors Phase 2,Phase 1
43 Dermatologic Agents Phase 2,Phase 1
44 Folic Acid Antagonists Phase 2
45 Vidarabine Phosphate Phase 2
46 Vitamin B Complex Phase 2
47 Antifungal Agents Phase 2,Phase 1
48 Hormones Phase 1, Phase 2
49 Hypoglycemic Agents Phase 1, Phase 2
50 insulin Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 62)

# Name Status NCT ID Phase Drugs
1 Retroviral Insertion Site Methodology Study Not yet recruiting NCT03311074 Phase 4
2 Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases Unknown status NCT01019876 Phase 2, Phase 3 Fludarabine;Cyclophosphamide;Cyclophosphamide 40;Cyclophosphamide 30
3 Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients Completed NCT00220766 Phase 3 Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified;Dextrose, 5% in Water
4 EZN-2279 in Patients With ADA-SCID Recruiting NCT01420627 Phase 3
5 Gene Therapy for X-linked Severe Combined Immunodeficiency Unknown status NCT01410019 Phase 1, Phase 2
6 MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID Completed NCT00794508 Phase 2
7 Gene Therapy for ADA-SCID Completed NCT00599781 Phase 1, Phase 2
8 IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency Completed NCT00228852 Phase 1, Phase 2 Busulfan, Fludarabine and ATG
9 Gene Therapy ADA Deficiency Completed NCT01279720 Phase 1, Phase 2
10 Cord Blood Stem Cell Transplantation Study (COBLT) Completed NCT00000603 Phase 2
11 Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants Recruiting NCT01512888 Phase 1, Phase 2 Busulfan
12 Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID) Recruiting NCT01306019 Phase 1, Phase 2 Busulfan
13 Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency Recruiting NCT03315078 Phase 1, Phase 2 Palifermin;Busulfan
14 Gene Transfer for SCID-X1 Using a Self-inactivating Lentiviral Vector Recruiting NCT03217617 Phase 1, Phase 2
15 Lentiviral Gene Therapy for Adenosine Deaminase (ADA) Deficiency Recruiting NCT01380990 Phase 1, Phase 2
16 Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning Recruiting NCT03311503 Phase 1, Phase 2
17 Immune Disorder HSCT Protocol Recruiting NCT01821781 Phase 2 Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
18 Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT Recruiting NCT01962415 Phase 2 Hydroxyurea;Alemtuzumab;Fludarabine;Melphalan;Thiotepa
19 Gene Transfer for Severe Combined Immunodeficiency, X-linked (SCID-X1) Using a Self-inactivating (SIN) Gammaretroviral Vector Active, not recruiting NCT01129544 Phase 1, Phase 2
20 Autologous Cryopreserved CD34+ Hematopoietic Cells Transduced With EFS-ADA Lentivirus for ADA SCID Active, not recruiting NCT02999984 Phase 1, Phase 2
21 Autologous Transplant of EFS-ADA Modified Bone Marrow Cells for ADA-Deficient Severe Combined Immunodeficiency (SCID) Active, not recruiting NCT01852071 Phase 1, Phase 2
22 ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID Active, not recruiting NCT00598481 Phase 2
23 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
24 Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases Enrolling by invitation NCT01852370 Phase 1, Phase 2
25 Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1 Terminated NCT00490100 Phase 1, Phase 2 Increlex
26 Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim Terminated NCT01182675 Phase 2 Transplant Conditioning with Mobilization Only;Transplant Conditioning with Mobilization and Alemtuzumab
27 SCID Bu/Flu/ATG Study With T Cell Depletion Terminated NCT02127892 Phase 1, Phase 2
28 Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders Terminated NCT00579137 Phase 1, Phase 2 Fludarabine
29 Sirolimus Prophylaxis for aGVHD in TME SCID Withdrawn NCT02177760 Phase 2 Sirolimus
30 A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders Unknown status NCT00596999 Phase 1
31 Transplantation of Hematopoietic Cells in Children With Severe Combined Immunodeficiency Syndrome Completed NCT00152100 Phase 1 Filgrastim, Alemtuzumab
32 Stem Cell Gene Therapy to Treat X-Linked Severe Combined Immunodeficiency (XSCID) Completed NCT00028236 Phase 1 Gene-Transduced Autologous CD34+ Stem Cells
33 Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency Completed NCT00018018 Phase 1 CD34+ cells transduced with ADA retrovir
34 Treatment of SCID Due to ADA Deficiency With Autologous Transplantation of Cord Blood or Hematopoietic CD 34+ Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector Completed NCT02022696 Phase 1
35 Multivirus-specific Cytotoxic T Lymphocytes (mCTL) Recruiting NCT02510404 Phase 1
36 Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow Transplant Active, not recruiting NCT00008450 Phase 1 Cyclosporine;Mycophenolate Mofetil
37 Human Placental-Derived Stem Cell Transplantation Active, not recruiting NCT01586455 Phase 1 Human Placental Derived Stem Cell
38 Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiency Not yet recruiting NCT02860559 Phase 1
39 Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases Terminated NCT02231710 Phase 1
40 Clinical Characteristics and Genetic Profiles of Severe Combined Immunodeficiency in China Unknown status NCT02231983
41 Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study Completed NCT00001255 ADA PBSC;ADA Umbilical Cord Blood Cells;Transduced Lymphocytes
42 Influences on Female Adolescents' Decisions Regarding Testing for Carrier Status of XSCID Completed NCT00006335
43 Newborn Screening for Severe Combined Immunodeficiency (SCID) in a High-Risk Population Completed NCT00845416
44 Developing Newborn Screening for Infants With Primary Immunodeficiency Completed NCT00113464
45 Neonatal Screening of Severe Combined Immunodeficiencies Recruiting NCT02590328
46 Genetic Basis of Immunodeficiency Recruiting NCT00055172
47 Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders Recruiting NCT00895271
48 Patients Treated for SCID (1968-Present) Recruiting NCT01346150
49 Natural History Study of SCID Disorders Recruiting NCT01186913
50 Evaluation of Patients With Immune Function Abnormalities Recruiting NCT00128973

Search NIH Clinical Center for Severe Combined Immunodeficiency

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Severe Combined Immunodeficiency cell therapies at LifeMap Discovery.

Genetic Tests for Severe Combined Immunodeficiency

Genetic tests related to Severe Combined Immunodeficiency:

# Genetic test Affiliating Genes
1 Severe Combined Immunodeficiency Disease 28
2 Severe Combined Immunodeficiency 28

Anatomical Context for Severe Combined Immunodeficiency

MalaCards organs/tissues related to Severe Combined Immunodeficiency:

38
T Cells, B Cells, Bone, Bone Marrow, Skin, Lung, Testes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Severe Combined Immunodeficiency:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Peripheral Blood B-cell Progenitor Cells Affected by disease
2 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
3 Blood Peripheral Blood Natural Killer Cells Affected by disease

Publications for Severe Combined Immunodeficiency

Articles related to Severe Combined Immunodeficiency:

(show top 50) (show all 859)
# Title Authors Year
1
BCGosis in Infants with Severe Combined ImmunoDeficiency (SCID). ( 29417456 )
2018
2
Late presenting atypical severe combined immunodeficiency (SCID) associated with a novel missense mutation in DCLRE1C. ( 28981982 )
2018
3
Maternal T and B cell engraftment in two cases of X-linked severe combined immunodeficiency with IgG1 gammopathy. ( 28780374 )
2017
4
Newborn screening for severe combined immunodeficiency: Evaluation of a commercial T-cell receptor excision circle-based method in Victorian dried blood spots. ( 28861919 )
2017
5
Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice. ( 28319446 )
2017
6
Inhibition of TRPML1 by lysosomal adenosine involved in severe combined immunodeficiency diseases. ( 28087698 )
2017
7
T Cell Lymphoma and Leukemia in Severe Combined Immunodeficiency Pigs following Bone Marrow Transplantation: A Case Report. ( 28747915 )
2017
8
Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Severe Combined Immunodeficiency Patients: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. ( 28068510 )
2017
9
A Practical Approach to Newborn Screening for Severe Combined Immunodeficiency Using the T Cell Receptor Excision Circle Assay. ( 29167668 )
2017
10
Haematopoietic stem cell transplantation for severe combined immunodeficiency: Long-term health outcomes and patient perspectives. ( 28513891 )
2017
11
A novel PAX1 null homozygous mutation in autosomal recessive otofaciocervical syndrome associated with severe combined immunodeficiency. ( 28657137 )
2017
12
FOXN1 deficient nude severe combined immunodeficiency. ( 28077132 )
2017
13
Identification of Novel JAK3 Mutations by Whole-Exome Sequencing in a Korean Boy With Severe Combined Immunodeficiency. ( 28570225 )
2017
14
Early diagnosis of severe combined immunodeficiency (SCID) in Turkey: a pilot study. ( 28814173 )
2017
15
Novel compound heterozygous mutations in ZAP70 in a Chinese patient with leaky severe combined immunodeficiency disorder. ( 28124082 )
2017
16
Topical Cidofovir for Recalcitrant Verrucae in Individuals with Severe Combined Immunodeficiency After Hematopoietic Stem Cell Transplantation. ( 27699886 )
2017
17
Mutation c.256_257delAA in RAG1 Gene in Polish Children with Severe Combined Immunodeficiency: Diversity of Clinical Manifestations. ( 28083621 )
2017
18
Acute Myeloid Leukemia in a Patient With X-linked Severe Combined Immunodeficiency. ( 28678090 )
2017
19
A novel mutation in the JH4 domain of JAK3 causing severe combined immunodeficiency complicated by vertebral osteomyelitis. ( 28917720 )
2017
20
Disseminated papular lesions as a unique manifestation heralding bacille Calmette-GuAcrin infection in a patient with T-B+NK- severe combined immunodeficiency. ( 28597928 )
2017
21
Medical Devices; Immunology and Microbiology Devices; Classification of the Newborn Screening Test for Severe Combined Immunodeficiency Disorder. Final order. ( 29091371 )
2017
22
A Droplet Digital PCR Method for Severe Combined Immunodeficiency Newborn Screening. ( 28826609 )
2017
23
Life-threatening systemic rotavirus infection after vaccination in Severe Combined Immunodeficiency (SCID). ( 28815852 )
2017
24
Newborn screening for severe combined immunodeficiency: a primer for clinicians. ( 29255099 )
2017
25
Hepatic Legionella pneumophila Infection in an Infant with Severe Combined Immunodeficiency. ( 28938259 )
2017
26
First Year of Israeli Newborn Screening for Severe Combined Immunodeficiency-Clinical Achievements and Insights. ( 29167666 )
2017
27
Long term outcomes of severe combined immunodeficiency: therapy implications. ( 28918671 )
2017
28
A Novel PGM3 Mutation Is Associated With a Severe Phenotype of Bone Marrow Failure, Severe Combined Immunodeficiency, Skeletal Dysplasia, and Congenital Malformations. ( 28543917 )
2017
29
Family History of Early Infant Death Correlates with Earlier Age at Diagnosis But Not Shorter Time to Diagnosis for Severe Combined Immunodeficiency. ( 28747913 )
2017
30
A case of severe combined immunodeficiency caused by adenosine deaminase deficiency with a new mutation. ( 28823388 )
2017
31
Modulatory effect of voriconazole on the production of proinflammatory cytokines in experimental cryptococcosis in mice with severe combined immunodeficiency. ( 29273275 )
2017
32
Identification of 22q11.2 Deletion Syndrome via Newborn Screening for Severe Combined Immunodeficiency. ( 28540525 )
2017
33
Severe combined immunodeficiency: From its discovery to the perspective. ( 28747600 )
2017
34
Development of fresh and vitrified agouti ovarian tissue after xenografting to ovariectomised severe combined immunodeficiency (SCID) mice. ( 28784201 )
2017
35
Pigs with Severe Combined Immunodeficiency Are Impaired in Controlling Influenza A Virus Infection. ( 27988511 )
2016
36
Generation of a Nonhuman Primate Model of Severe Combined Immunodeficiency Using Highly Efficient Genome Editing. ( 27374787 )
2016
37
Neonatal screening for severe combined immunodeficiency in Brazil. ( 27207231 )
2016
38
Interleukin-15 deficiency promotes the development of T-cell acute lymphoblastic leukemia in non-obese diabetes mice with severe combined immunodeficiency. ( 26876593 )
2016
39
Functional changes in gut microbiota during hematopoietic stem cell transplantation for severe combined immunodeficiency. ( 27118218 )
2016
40
Maternal T-Cell Engraftment Interferes With Human Leukocyte Antigen Typing in Severe Combined Immunodeficiency. ( 26834123 )
2016
41
Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency. ( 27099176 )
2016
42
NK cells are intrinsically functional in pigs with Severe Combined Immunodeficiency (SCID) caused by spontaneous mutations in the Artemis gene. ( 27269786 )
2016
43
Saccharomyces kluyveri Fungemia in an Infant with Severe Combined Immunodeficiency. ( 27771657 )
2016
44
Necrotizing Retinitis Secondary to Congenital Cytomegalovirus Infection Associated with Severe Combined Immunodeficiency. ( 27999698 )
2016
45
Biallelic modification of IL2RG leads to severe combined immunodeficiency in pigs. ( 27809915 )
2016
46
Deep intronic mis-splicing mutation in JAK3 gene underlies T-B+NK- severe combined immunodeficiency phenotype. ( 26769277 )
2016
47
Case Report: Whole exome sequencing identifies variation c.2308G>A p.E770K in<i>RAG1</i>associated with B- T- NK+ severe combined immunodeficiency. ( 29067161 )
2016
48
Guidelines for Screening, Early Diagnosis and Management of Severe Combined Immunodeficiency (SCID) in India. ( 26920398 )
2016
49
Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand? ( 26790362 )
2016
50
Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B. ( 27959755 )
2016

Variations for Severe Combined Immunodeficiency

ClinVar genetic disease variations for Severe Combined Immunodeficiency:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 IL7R NM_002185.4(IL7R): c.353G> A (p.Cys118Tyr) single nucleotide variant Pathogenic rs193922641 GRCh37 Chromosome 5, 35867539: 35867539
2 JAK3 NM_000215.3(JAK3): c.1767C> T (p.Gly589=) single nucleotide variant Pathogenic/Likely pathogenic rs193922362 GRCh37 Chromosome 19, 17947957: 17947957
3 JAK3 NM_000215.3(JAK3): c.678_679delCT (p.Cys227Profs) deletion Pathogenic/Likely pathogenic rs193922364 GRCh37 Chromosome 19, 17953307: 17953308
4 RAG1 NM_000448.2(RAG1): c.322C> T (p.Arg108Ter) single nucleotide variant Pathogenic/Likely pathogenic rs193922464 GRCh37 Chromosome 11, 36595176: 36595176

Copy number variations for Severe Combined Immunodeficiency from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 209902 16 28100000 34600000 Deletion CORO1A Severe combined immunodeficiency

Expression for Severe Combined Immunodeficiency

Search GEO for disease gene expression data for Severe Combined Immunodeficiency.

Pathways for Severe Combined Immunodeficiency

Pathways related to Severe Combined Immunodeficiency according to GeneCards Suite gene sharing:

(show all 47)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.98 CD3D CD3E IL2 IL2RG IL7 IL7R
2
Show member pathways
13.81 CD3D CD3E IL2 IL2RG IL7 IL7R
3
Show member pathways
13.64 CD3D CD3E IL2 IL2RG IL7 IL7R
4
Show member pathways
13.35 IL2 IL2RG IL7 IL7R IL9 JAK3
5
Show member pathways
13.32 CD3D CD3E IL2 IL2RG IL7 IL7R
6
Show member pathways
12.84 CD3D CD3E IL2 IL9 RFX5 RFXAP
7 12.82 IL2 IL2RG IL7 IL7R JAK3
8
Show member pathways
12.78 CD3D CD3E IL2 IL2RG JAK3
9
Show member pathways
12.75 IL2 IL2RG IL7 IL7R IL9 JAK3
10
Show member pathways
12.62 CD3D CD3E IL2 PTPRC ZAP70
11
Show member pathways
12.54 CD3D CD3E IL2 IL2RG JAK3 ZAP70
12 12.47 DCLRE1C LIG4 NHEJ1 PRKDC
13 12.4 CD3D CD3E IL2 IL2RG JAK3
14
Show member pathways
12.38 CD3D CD3E IL2 IL9 PTPRC ZAP70
15 12.38 CD3E DCLRE1C IL2 JAK3 PTPRC RAG1
16
Show member pathways
12.35 DCLRE1C LIG4 NHEJ1 PRKDC
17
Show member pathways
12.33 CD3D CD3E PTPRC ZAP70
18
Show member pathways
12.29 CD3D CD3E PTPRC ZAP70
19
Show member pathways
12.29 CD3D CD3E IL2 IL2RG PTPRC ZAP70
20
Show member pathways
12.26 IL2 IL2RG IL7 IL7R IL9 JAK3
21
Show member pathways
12.11 CD3D CD3E IL2 ZAP70
22
Show member pathways
11.97 CD3D CD3E IL2 IL2RG
23
Show member pathways
11.95 CD3D CD3E PTPRC ZAP70
24
Show member pathways
11.94 CD3D CD3E PTPRC ZAP70
25 11.92 CD3E IL2 IL7 IL7R PTPRC
26 11.85 IL2 IL7R JAK3 PTPRC
27 11.85 CD3D CD3E IL7 IL7R
28
Show member pathways
11.83 CD3E IL2RG JAK3
29 11.74 CD3D CD3E PTPRC
30 11.72 CD3D CD3E ZAP70
31 11.71 CD3E IL2 IL7R PTPRC
32 11.7 CD3D CD3E ZAP70
33
Show member pathways
11.67 IL2 IL2RG JAK3
34 11.67 IL2 IL7 IL7R IL9 PTPRC
35
Show member pathways
11.6 CD3D CD3E IL2 IL2RG
36 11.56 CD3E IL7R PTPRC
37 11.53 CD3D CD3E ZAP70
38
Show member pathways
11.37 CD3D IL2 IL2RG
39 11.32 IL2 IL2RG ZAP70
40 11.32 CD3E IL2 IL2RG IL9 JAK3
41 11.21 CD3D CD3E IL2
42
Show member pathways
11.2 IL2RG IL7 IL7R IL9 JAK3
43 11.16 CD3E IL2 IL9
44 11.1 DCLRE1C LIG4 PRKDC
45 11 ADA CD3D CD3E DCLRE1C IL2RG IL7R
46 10.88 IL2RG IL7 IL7R JAK3 RAG1 RAG2
47 10.77 IL2RG IL9

GO Terms for Severe Combined Immunodeficiency

Cellular components related to Severe Combined Immunodeficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.55 ADA CD3E IL2RG IL7R PTPRC
2 alpha-beta T cell receptor complex GO:0042105 9.37 CD3D CD3E
3 DNA-dependent protein kinase-DNA ligase 4 complex GO:0005958 9.32 LIG4 PRKDC
4 DNA ligase IV complex GO:0032807 9.26 LIG4 NHEJ1
5 T cell receptor complex GO:0042101 9.13 CD3D CD3E ZAP70
6 nonhomologous end joining complex GO:0070419 8.92 DCLRE1C LIG4 NHEJ1 PRKDC

Biological processes related to Severe Combined Immunodeficiency according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.98 CD3D CD3E IL7R PTPRC
2 T cell receptor signaling pathway GO:0050852 9.93 CD3D CD3E PTPRC ZAP70
3 double-strand break repair via nonhomologous end joining GO:0006303 9.88 DCLRE1C LIG4 NHEJ1 PRKDC
4 double-strand break repair GO:0006302 9.87 DCLRE1C LIG4 NHEJ1 PRKDC
5 adaptive immune response GO:0002250 9.87 CD3D CD3E DCLRE1C IL2 JAK3 RAG1
6 positive regulation of T cell proliferation GO:0042102 9.86 CD3E IL2 JAK3 PTPRC
7 DNA recombination GO:0006310 9.85 DCLRE1C LIG4 NHEJ1 PRKDC RAG1 RAG2
8 response to ionizing radiation GO:0010212 9.84 DCLRE1C LIG4 NHEJ1 PRKDC
9 T cell activation GO:0042110 9.82 ADA CD3E ZAP70
10 positive regulation of B cell proliferation GO:0030890 9.81 ADA IL2 IL7 PTPRC
11 interleukin-7-mediated signaling pathway GO:0038111 9.8 IL2RG IL7 IL7R JAK3
12 B cell differentiation GO:0030183 9.8 DCLRE1C JAK3 NHEJ1 RAG1 RAG2
13 response to gamma radiation GO:0010332 9.77 LIG4 PRKDC PTPRC
14 positive regulation of calcium-mediated signaling GO:0050850 9.76 ADA CD3E ZAP70
15 regulation of T cell differentiation GO:0045580 9.67 ADA RAG1
16 interleukin-15-mediated signaling pathway GO:0035723 9.67 IL2RG JAK3
17 positive regulation of organ growth GO:0046622 9.67 IL7 RAG2
18 positive regulation of alpha-beta T cell differentiation GO:0046638 9.66 ADA ZAP70
19 negative thymic T cell selection GO:0045060 9.66 CD3E ZAP70
20 positive regulation of T cell differentiation in thymus GO:0033089 9.65 ADA IL7R
21 positive regulation of alpha-beta T cell proliferation GO:0046641 9.65 CD3E ZAP70
22 positive thymic T cell selection GO:0045059 9.65 CD3D ZAP70
23 negative regulation of thymocyte apoptotic process GO:0070244 9.65 ADA JAK3 RAG1
24 T cell differentiation in thymus GO:0033077 9.65 CD3E LIG4 PRKDC RAG1 RAG2
25 negative regulation of T cell mediated cytotoxicity GO:0001915 9.64 IL7R PTPRC
26 T cell receptor V(D)J recombination GO:0033153 9.63 LIG4 PRKDC
27 T cell lineage commitment GO:0002360 9.63 IL7 PRKDC RAG2
28 pro-B cell differentiation GO:0002328 9.62 LIG4 PRKDC
29 interleukin-4-mediated signaling pathway GO:0035771 9.62 IL2RG JAK3
30 B cell lineage commitment GO:0002326 9.61 PRKDC RAG2
31 immunoglobulin V(D)J recombination GO:0033152 9.61 LIG4 PRKDC
32 interleukin-9-mediated signaling pathway GO:0038113 9.61 IL2RG IL9 JAK3
33 pre-B cell allelic exclusion GO:0002331 9.6 RAG1 RAG2
34 positive regulation of T cell differentiation GO:0045582 9.55 ADA IL2 IL7 RAG1 ZAP70
35 V(D)J recombination GO:0033151 9.35 DCLRE1C LIG4 PRKDC RAG1 RAG2
36 T cell differentiation GO:0030217 9.17 CD3D IL2 IL7R NHEJ1 PTPRC RAG2
37 immune system process GO:0002376 10.09 CD3D CD3E DCLRE1C IL2 JAK3 PRKDC
38 immune response GO:0006955 10.07 IL2 IL2RG IL7 IL7R IL9 RAG1

Molecular functions related to Severe Combined Immunodeficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.13 IL2 IL2RG JAK3
2 interleukin-7 receptor activity GO:0004917 8.62 IL2RG IL7R

Sources for Severe Combined Immunodeficiency

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....